These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18386618)

  • 1. Glycoregulation disorders and alterations of C reactive protein in nonalcoholic fatty liver disease.
    Casoinic F; Sâmpelean D; Badău C
    Rom J Intern Med; 2006; 44(4):419-26. PubMed ID: 18386618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease.
    Vanjiappan S; Hamide A; Ananthakrishnan R; Periyasamy SG; Mehalingam V
    Diabetes Metab Syndr; 2018 Jul; 12(4):479-482. PubMed ID: 29402657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome.
    Mohan V; Farooq S; Deepa M; Ravikumar R; Pitchumoni CS
    Diabetes Res Clin Pract; 2009 Apr; 84(1):84-91. PubMed ID: 19168251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic steatosis in obese Chinese children.
    Chan DF; Li AM; Chu WC; Chan MH; Wong EM; Liu EK; Chan IH; Yin J; Lam CW; Fok TF; Nelson EA
    Int J Obes Relat Metab Disord; 2004 Oct; 28(10):1257-63. PubMed ID: 15278103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit?
    Almobarak AO; Barakat S; Suliman EA; Elmadhoun WM; Mohamed NA; Abobaker IO; Noor SK; Bushara SO; Ahmed MH
    Arab J Gastroenterol; 2015 Jun; 16(2):54-8. PubMed ID: 26174761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
    Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
    J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease--a risk factor for microalbuminuria in type 2 diabetic patients.
    Casoinic F; Sâmpelean D; Bădău C; Prună L
    Rom J Intern Med; 2009; 47(1):55-9. PubMed ID: 19886070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease.
    Canbakan B; Senturk H; Tahan V; Hatemi I; Balci H; Toptas T; Sonsuz A; Velet M; Aydin S; Dirican A; Ozgulle S; Ozbay G
    Acta Gastroenterol Belg; 2007; 70(3):277-84. PubMed ID: 18074737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).
    Kalra S; Vithalani M; Gulati G; Kulkarni CM; Kadam Y; Pallivathukkal J; Das B; Sahay R; Modi KD
    J Assoc Physicians India; 2013 Jul; 61(7):448-53. PubMed ID: 24772746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
    Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
    Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease.
    Angelico F; Del Ben M; Conti R; Francioso S; Feole K; Fiorello S; Cavallo MG; Zalunardo B; Lirussi F; Alessandri C; Violi F
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1578-82. PubMed ID: 15598693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
    Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
    Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis].
    Choi SY; Kim D; Kang JH; Park MJ; Kim YS; Lim SH; Kim CH; Lee HS
    Korean J Hepatol; 2008 Mar; 14(1):77-88. PubMed ID: 18367860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
    Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients.
    Zimmermann E; Anty R; Tordjman J; Verrijken A; Gual P; Tran A; Iannelli A; Gugenheim J; Bedossa P; Francque S; Le Marchand-Brustel Y; Clement K; Van Gaal L; Sørensen TIA; Jess T
    J Hepatol; 2011 Sep; 55(3):660-665. PubMed ID: 21238518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-sensitivity C-reactive protein is a strong predictor of non-alcoholic fatty liver disease.
    Yeniova AO; Küçükazman M; Ata N; Dal K; Kefeli A; Başyiğit S; Aktaş B; Ağladioğlu K; Akin KO; Ertugrul DT; Nazligül Y; Beyan E
    Hepatogastroenterology; 2014; 61(130):422-5. PubMed ID: 24901154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).
    Ortiz-Lopez C; Lomonaco R; Orsak B; Finch J; Chang Z; Kochunov VG; Hardies J; Cusi K
    Diabetes Care; 2012 Apr; 35(4):873-8. PubMed ID: 22374640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.